Loading publications…
The last 5 uploaded publications
Clinical Application of Poly(ADP-ribose) Polymerase (PARP) Inhibitors in Prostate Cancer
Andrisha–Jade Inderjeeth, Monique Topp, Elaine Sanij, Elena Castro, Shahneen Sandhu (2022). Clinical Application of Poly(ADP-ribose) Polymerase (PARP) Inhibitors in Prostate Cancer. , 14(23), DOI: https://doi.org/10.3390/cancers14235922.
Article62 days agoNiraparib and Abiraterone Acetate plus Prednisone in Metastatic Castration-resistant Prostate Cancer: Final Overall Survival Analysis for the Phase 3 MAGNITUDE Trial
Kim N., Elena Castro, G. Attard, Matthew R. Smith, Shahneen Sandhu, Eleni Efstathiou, Guilhem Roubaud, Eric J. Small, A Gomes, Dana E. Rathkopf, Marniza Saad, Howard Gurney, Wonho Jung, Won Kim, Shiva Dibaj, Daphne Wu, Jenny Zhang, Angela Lopez‐Gitlitz, Peter Francis, David Olmos (2025). Niraparib and Abiraterone Acetate plus Prednisone in Metastatic Castration-resistant Prostate Cancer: Final Overall Survival Analysis for the Phase 3 MAGNITUDE Trial. , DOI: https://doi.org/10.1016/j.euo.2025.04.012.
Article62 days agoImpact of run-in treatment with abiraterone acetate and prednisone (AAP) in the MAGNITUDE study of niraparib (NIRA) and AAP in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations.
Elena Castro, Kim N., Shahneen Sandhu, David Olmos, Gerhardt Attard, Marniza Saad, Andrea Juliana Gomes, Dana E. Rathkopf, Matthew R. Smith, Taek Won Kang, Felipe Melo Cruz, Umberto Basso, Gary Mason, Adam del Corral, Shiva Dibaj, Daphne Wu, Brooke Diorio, Angela Mennicke Lopez- Gitlitz, Deniz Tural, Eric J. Small (2023). Impact of run-in treatment with abiraterone acetate and prednisone (AAP) in the MAGNITUDE study of niraparib (NIRA) and AAP in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations.. , 41(6_suppl), DOI: https://doi.org/10.1200/jco.2023.41.6_suppl.172.
Article62 days agoManagement of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC)
Ana M. Aparicio, Andrew J. Armstrong, Diogo Assed Bastos, Gerhardt Attard, Karol Axcrona, Mouna Ayadi, Himisha Beltran, Anders Bjartell, Pierre Blanchard, María T. Bourlon, Alberto Briganti, Muhammad Bulbul, Consuelo Buttigliero, Orazio Caffo, Daniel Castellano, Elena Castro, Heather H. Cheng, Kim N., Caroline S. Clarke, Noel W. Clarke, Johann S. de Bono, Maria De Santis, Ignacio Durán, Eleni Efstathiou, Onyeanunam Ngozi Ekeke, Tamer I H El Nahas, Louise Emmett, Stefano Fanti, Omolara Fatiregun, Felix Y. Feng, Peter C.C. Fong, Valérie Fonteyne, Nicola Fossati, Daniel J. George, Martin Gleave, Gwénaëlle Gravis, Susan Halabi, Daniel Heinrich, Ken Herrmann, Michael S. Hofman, Thomas A. Hope, Lisa G. Horvath, Maha Hussain, Barbara Alicja Jereczek‐Fossa, Robert J. Jones, Anthony M. Joshua, R. Kanesvaran, Daniel Keizman, Raja B. Khauli, Gero Kramer, Stacy Loeb, Brandon A. Mahal, Fernando Cotait Maluf, Joaquı́n Mateo, David Matheson, Mika Matikainen, Ray McDermott, Rana R. McKay, Niven Mehra, Axel S. Merseburger, Alicia K. Morgans, Michael J. Morris, Hind Mrabti, Deborah Mukherji, Silke Gillessen, Fabio Turco, Ian D. Davis, Jason A. Efstathiou, Karim Fizazi, Nicholas D. James, Neal D. Shore, Eric J. Small, Matthew R. Smith, Christopher J. Sweeney, Bertrand Tombal, Thomas Zilli, Neeraj Agarwal, Emmanuel S. Antonarakis, Declan G. Murphy, Vedang Murthy, Shingai B.A. Mutambirwa, Paul L. Nguyen, William Oh, Piet Ost, Joe M. O’Sullivan, Anwar R. Padhani, Chris Parker, Darren M.C. Poon, Colin C. Pritchard, Danny Rabah, Dana E. Rathkopf, Robert E. Reiter, Raphaële Renard‐Penna, Charles J. Ryan, Fred Saad, Juan Pablo Sade, Shahneen Sandhu, Oliver A. Sartor, Edward M. Schaeffer, Howard I. Scher (2024). Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC). , DOI: https://doi.org/10.1016/j.eururo.2024.09.017.
Article62 days agoLBA85 Niraparib (NIRA) with abiraterone acetate plus prednisone (AAP) as first-line (1L) therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations: Three-year update and final analysis (FA) of MAGNITUDE
K.N. Chi, Elena Castro, Gerhardt Attard, Matthew R. Smith, Shahneen Sandhu, Eleni Efstathiou, Guilhem Roubaud, Eric J. Small, A.J.P.D.S. Gomes, Dana E. Rathkopf, Marniza Saad, Howard Gurney, Wonho Jung, Gary Mason, Shiva Dibaj, Daphne Wu, B. Diorio, Angela Lopez‐Gitlitz, W. Kim, David Olmos (2023). LBA85 Niraparib (NIRA) with abiraterone acetate plus prednisone (AAP) as first-line (1L) therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations: Three-year update and final analysis (FA) of MAGNITUDE. , 34, DOI: https://doi.org/10.1016/j.annonc.2023.10.087.
Article62 days ago